Skip to main content
Clinical Trials/NCT03217552
NCT03217552
Unknown
N/A

An Observational Study to Evaluate the Diagnostic and Predictive Accuracy of the Mologic Biomarker Panel in Patientsrnwith Severe Infection

Mologic Ltd1 site in 1 country600 target enrollmentNovember 26, 2017
ConditionsSepsisInfection

Overview

Phase
N/A
Intervention
Not specified
Conditions
Sepsis
Sponsor
Mologic Ltd
Enrollment
600
Locations
1
Primary Endpoint
Biomarkers and results from routine clinical testing for infection
Last Updated
8 years ago

Overview

Brief Summary

This study is a prospective, single center, observational, cohort study of patients to determine whether the Mologic Biomarker Panel can identify patients with infection from those without, including those with other reasons for inflammation (e.g. post-operative). It will also assess whether it has the potential to judge the severity of illness, prognosticate outcome and guide antibiotic therapy.

The aim is to recruit patients who are "representative" of patients with suspected sepsis, uncomplicated infection, or non-infection related critical illness that require critical care intervention and assessment.

This study is observational and will not alter patient management or the standard of care. The results from the investigational Mologic Biomarker Panel and associated research assays will not be provided to treating clinicians, or used in any manner to affect patient care.

The study will take place over approximately an 18-month period and it is anticipated that approximately 600 patients will be collectively enrolled. The study aims to recruit patients from three environments within UCLH:

  • The Emergency Department.
  • Critical Care Unit
  • Patients undergoing major surgery
Registry
clinicaltrials.gov
Start Date
November 26, 2017
End Date
July 2019
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • ≥ 18 years old
  • Investigated for potential infection (the clinical need for a blood culture)

Exclusion Criteria

  • \<18 years old
  • Severe anaemia (\<60g/dl) and contra-indication to transfusion
  • Unable to gain consent or agreement
  • Treated with palliative intent
  • Blood culture indicated for screening or monitoring

Outcomes

Primary Outcomes

Biomarkers and results from routine clinical testing for infection

Time Frame: 18 months

Research assay will be used to test for the investigational Mologic biomarker panel and these results will be assessed using the results obtained from conventional testing used to identify infection (such as white cell count and CRP), in order to find a clinical association with the mologic biomarkers and patients with infections.

Study Sites (1)

Loading locations...

Similar Trials